Zobrazeno 1 - 10
of 739
pro vyhledávání: '"Axel Hauschild"'
Autor:
Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for cur
Externí odkaz:
https://doaj.org/article/85c0508e98f2481db714933c819add16
Autor:
Paolo A. Ascierto, Christian Blank, Alexander M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. Luke, Janice M. Mehnert, Jeffrey A. Sosman, Hussein A. Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-ly
Externí odkaz:
https://doaj.org/article/72b5639fd85f4c0aa3e6387485d98c32
Autor:
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, Jan Christoph Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these pati
Externí odkaz:
https://doaj.org/article/b02d789393944e89a582fe64cc6e6ada
Autor:
Celeste Lebbe, Parminder Singh, Omid Hamid, Frances A Collichio, Igor Puzanov, Merrick Ross, Theodore Logan, Philip Friedlander, Claus Garbe, Janice M Mehnert, John Glaspy, Axel Hauschild, Wendy Snyder, Jason A Chesney, Mohammed M Milhem, Harshada Joshi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II stud
Externí odkaz:
https://doaj.org/article/c5ed9be44801480e823ebf02761b3964
Autor:
Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. Methods Recur
Externí odkaz:
https://doaj.org/article/26a1f6c183d346e98b0aeea13c640df3
Autor:
Julia Höhn, Achim Hekler, Eva Krieghoff-Henning, Jakob Nikolas Kather, Jochen Sven Utikal, Friedegund Meier, Frank Friedrich Gellrich, Axel Hauschild, Lars French, Justin Gabriel Schlager, Kamran Ghoreschi, Tabea Wilhelm, Heinz Kutzner, Markus Heppt, Sebastian Haferkamp, Wiebke Sondermann, Dirk Schadendorf, Bastian Schilling, Roman C Maron, Max Schmitt, Tanja Jutzi, Stefan Fröhling, Daniel B Lipka, Titus Josef Brinker
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 7, p e20708 (2021)
BackgroundRecent years have been witnessing a substantial improvement in the accuracy of skin cancer classification using convolutional neural networks (CNNs). CNNs perform on par with or better than dermatologists with respect to the classification
Externí odkaz:
https://doaj.org/article/a779626d04dc4f8b9a5153b998562609
Autor:
Andreas Stang, Axel Hauschild
Publikováno v:
The Lancet Regional Health. Europe, Vol 2, Iss , Pp 100040- (2021)
Externí odkaz:
https://doaj.org/article/651b0af1cb3d414fa16fad5cdfde01f3
Autor:
Peter Mohr, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, Jessica C. Hassel, Axel Hauschild, Rudolf Herbst, Ruixuan Jiang, Katharina C. Kähler, Clemens Krepler, Alexander Kreuter, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Claudia Pföhler, Anja Rudolph, Dirk Schadendorf, Maximo Schiavone, Gaston Schley, Patrick Terheyden, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Julia Welzel, Michael Weichenthal
Publikováno v:
Cancers, Vol 14, Iss 7, p 1804 (2022)
Knowledge on the real-world characteristics and outcomes of pembrolizumab-treated advanced melanoma patients in Germany and on the value of different real-world endpoints as surrogates for overall survival (OS) is limited. A sample of 664 pembrolizum
Externí odkaz:
https://doaj.org/article/bb3e4f856a0049c7af31270a7328f54b
Autor:
Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Karijn P M Suijkerbuijk, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Osama E Rahma, Paul C Lorigan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Externí odkaz:
https://doaj.org/article/a11788d6e7784eafb0cbc66b79d31b22
Autor:
Dirk Schadendorf, Carola Berking, Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Paolo Antonio Ascierto, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Georgina V Long, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Carlo Alberto Tondini, Leyre Zubiri, Arielle Elkrief, Karijn P M Suijkerbuijk, Mario Mandala, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Matteo S Carlino, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Kerry L Reynolds, Osama E Rahma, Paul C Lorigan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI)
Externí odkaz:
https://doaj.org/article/0880e80bb8394806afbc90b0e9140059